The effect of coronavirus disease (COVID-19) pandemic on idiopathic inflammatory myositis patients: a single centre experience
Authors' conclusion
Based on our results, myositis may be associated with an increased risk of COVID-19 infection. Independent risk factor for hospitalisation are longer disease duration and anti-Jo1 positivity.
Study context
- Population
- Patients with idiopathic inflammatory myopathies (IIM), single centre101 had blood tests
- Participants
- 176 patients
- Exposure
- IIM cohort vs national prevalence of COVID-19
- Outcome
- Incidence of COVID-19 infection
- Follow-up
- By June 1st, 2021
Methodological detailsretrospective, single-centre
- Retrospective
- Single-centre
Main finding
As reported in the abstract
COVID-19 infection incidence
Incidence of COVID-19 infections in IIM cohort
34.7%
National prevalence
8.2%
Observational data: associations, not effects.
Further findings
Infection severity and hospitalisation
- A third of infections asymptomatic or mild
- Hospitalised patients had significantly longer disease duration and higher incidence of anti-Jo-1 antibody
- All infected patients became seropositive regardless of immunosuppressive therapy or symptom severity
Vaccination and humoral response
- Received anti-COVID-19 vaccine
- 54.3%
- Seropositive after vaccination
- 72.3%
- Higher anti-spike titer after Pfizer-BioNTech vs others
- Decreased post-vaccination antibody response with steroid therapy vs without
Safety
Major post-vaccination infection
- None observed
- 0
Original publication
The effect of COVID-19 pandemic on idiopathic inflammatory myositis patients: a single centre experience. Clin Exp Rheumatol. Published 12 February 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →